An In Vitro Model of Glioma Development

Genes (Basel). 2023 Apr 27;14(5):990. doi: 10.3390/genes14050990.

Abstract

Gliomas are the prevalent forms of brain cancer and derive from glial cells. Among them, astrocytomas are the most frequent. Astrocytes are fundamental for most brain functions, as they contribute to neuronal metabolism and neurotransmission. When they acquire cancer properties, their functions are altered, and, in addition, they start invading the brain parenchyma. Thus, a better knowledge of transformed astrocyte molecular properties is essential. With this aim, we previously developed rat astrocyte clones with increasing cancer properties. In this study, we used proteomic analysis to compare the most transformed clone (A-FC6) with normal primary astrocytes. We found that 154 proteins are downregulated and 101 upregulated in the clone. Moreover, 46 proteins are only expressed in the clone and 82 only in the normal cells. Notably, only 11 upregulated/unique proteins are encoded in the duplicated q arm of isochromosome 8 (i(8q)), which cytogenetically characterizes the clone. Since both normal and transformed brain cells release extracellular vesicles (EVs), which might induce epigenetic modifications in the neighboring cells, we also compared EVs released from transformed and normal astrocytes. Interestingly, we found that the clone releases EVs containing proteins, such as matrix metalloproteinase 3 (MMP3), that can modify the extracellular matrix, thus allowing invasion.

Keywords: astrocyte cell lines; astrocytomas; chromosome alterations; epigenetic alterations; extracellular vesicles (EVs); metalloproteinases; proteomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / metabolism
  • Brain / metabolism
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Glioma* / genetics
  • Glioma* / metabolism
  • Proteins / metabolism
  • Proteomics
  • Rats

Substances

  • Proteins

Grants and funding

This work was partially supported by FFR 2021-2022-2023 of University of Palermo to F.C., C.M.D., G.S., P.C. and F.N., and by NBFC to University of Palermo, funded by the Italian Ministry of University and Research, PNRR, Missione 4 Componente 2, “Dalla ricerca all’impresa”, Investimento 1.4, Project CN00000033 (F.C.). S.D.S was supported by Fondazione con il Sud under the Programme “Brains to South 2018”—Project “iRhom2: a new therapeutic target in osteoarthritis” (Grant Agreement No. 2018—PDR—00799) and by “National Biodiversity Future Center—NBFC” (CUP: B73C2100130006) CN_00000033—PNRR—M4C2—CN5 Spoke 6.